Saturday, January 19, 2019
This HND piece focuses on two items: A new diagnostic for colorectal cancer that seems every bit as effective as a colonoscopy, and requires only a simple blood draw; and some controversies that are sure to arise as CBD becomes a mainstream drug.
While colonoscopy is the gold standard, many people for whom this test is indicated do not comply. It is certainly invasive, and requires a prep that is not as nasty as some years ago, but is still a bit unpleasant. The new blood test from CellMax Life looks impressive in trials.
As to CBD, Epidiolex—a purified CBD extract boasting an FDA approval (for certain seizure disorders)—is looking for great things. Only, it will cost more than $30,000 per year. This is ironic, since CBD has long been known to have wonderful anti-seizure properties, and has been used for this purpose for a number of years. Look for the insurance industry to push back. Fun, fun, fun.
Read the complete article.
Interscan Corporation
4590 Ish Drive
Simi Valley, CA 93063-7682
Phone: 1 800 458-6153 (US and Canada)
(818) 882-2331
FAX: (818) 341-0642
Web: www.gasdetection.com
